Printer Friendly

Elusys Therapeutics, USAMRIID Continue Work on Developing Biowarfare Therapeutics.

SciTech21-13 December 2006-Elusys Therapeutics, USAMRIID Continue Work on Developing Biowarfare Therapeutics(C)2006 JeraOne - http://www.jeraone.com

Elusys Therapeutics Inc., a developer of targeted anti-infective therapeutics, today announced that it has extended its Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to continue the collaborative research on therapeutics against anthrax and other unspecified biowarfare agents.

The research will use Elusys' HP Antibody technology.

"Elusys' work in biodefense began in 2000 with the initial USAMRIID collaboration and our anthrax therapeutic, Anthim, evolved from that early research," said George Elston, vice president of Finance & Government Affairs at Elusys Therapeutics. "Elusys has since advanced Anthim into the final stages of clinical development and today, this important countermeasure is well-positioned for stockpiling by the U.S. government under Project BioShield.

"The new CRDA extension will focus on the application of the Elusys HP Antibody technology as a platform for developing safe and effective countermeasures against biowarfare agents and other emerging infections," said Elston. "We look forward to continuing this important collaboration with USAMRIID."

Elusys has received funding from the Department of Defense and the National Institutes of Health to accelerate the development of Anthim and the HP Antibody technology. In total, the company has received over $20 million from the U.S. government for these programs.

Anthim is a high-affinity monoclonal antibody, targeting the anthrax toxin Protective Antigen. It has demonstrated significant efficacy against anthrax infection in lethal animal spore challenge studies, and has been demonstrated to be safe and well tolerated when administered with and without antibiotics in a human safety study.

Being developed for prophylaxis and post-exposure treatment of inhalation anthrax, Anthim has been granted Fast-Track status and Orphan Drug Designation by the FDA and is being developed under the FDA Animal Rule, a regulatory process specifically designed for the development of medical countermeasures to bioterror threats.

Elusys is a privately held biopharmaceutical company. Current investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures and MedImmune Ventures. For more information, visit www.elusys.com.

((Comments on this story may be sent to newsdesk@jeraone.com))

((Distributed via M2 Communications Ltd - http://www.m2.com))
COPYRIGHT 2006 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:SciTech21
Date:Dec 13, 2006
Words:365
Previous Article:Enova Systems, Tokyo R&D Team Up on Electric Bus for Japanese Power Company.
Next Article:Cougar Biotechnology Initiates Phase II Trial of Prostate Cancer Drug in UK.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters